Impact News +++ Carl Icahn′s top Q3 moves include new stake in EchoStar, exiting Bausch Health (SeekingAlpha) +++ ECHOSTAR Aktie -4,17%

INSMED Aktie

>INSMED Aktienkurs

169 EUR +2.4% (Tradegate)

Ask: 168 EUR / 150 Stück

Bid: 165 EUR / 160 Stück

Tagesumsatz: 777 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INSMED Aktie über LYNX handeln

Intraday

1 Jahr

>INSMED Performance

1 Woche: +5,6%

1 Monat: +19,9%

3 Monate: +53,6%

6 Monate: +191,4%

1 Jahr: +141,4%

laufendes Jahr: +156,1%

>INSMED Aktie

Name:

INSMED INC. DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US4576693075 / A1JJA3

Symbol/ Ticker:

IM8N (Frankfurt) / INSM (NASDAQ)

Kürzel:

FRA:IM8N, ETR:IM8N, IM8N:GR, NASDAQ:INSM

Index:

Webseite:

https://insmed.com/

Profil:

Insmed Inc. is a biopharmaceutical company dedicat..
>Volltext..

Marktkapitalisierung:

35047.14 Mio. EUR

Unternehmenswert:

34249.66 Mio. EUR

Umsatz:

384.68 Mio. EUR

EBITDA:

-840.45 Mio. EUR

Nettogewinn:

-1018.75 Mio. EUR

Gewinn je Aktie:

-5.32 EUR

Schulden:

641.17 Mio. EUR

Liquide Mittel:

288.08 Mio. EUR

Operativer Cashflow:

-760.2 Mio. EUR

Bargeldquote:

4.03

Umsatzwachstum:

23.68%

Gewinnwachstum:

-29.97%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 16.728.766 USD.

Suchwörter:

INSMED

Letzte Datenerhebung:

15.11.25

>INSMED Kennzahlen

Aktien/ Unternehmen:

Aktien: 213.27 Mio. St.

Frei handelbar: 98.07%

Leerverk. Aktien: 3.8%

Rückkaufquote: -2.3%

Mitarbeiter: 1271

Umsatz/Mitarb.: 0.25 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 7.83%

Bewertung:

KGV: -

KGV lG: -

KUV: 92.02

KBV: 44.32

PEG-Ratio: -2.79

EV/EBITDA: -

Rentabilität:

Bruttomarge: 75.35%

Gewinnmarge: -264.83%

Operative Marge: -221.53%

Managementeffizenz:

Gesamtkaprendite: -53.64%

Eigenkaprendite: -165.69%

>INSMED Peer Group

Es sind 599 Aktien bekannt.

>INSMED Chart & Kurs - NASDAQ

>INSMED News

15.11.25 - 02:01	Insiderhandel: Chief People Strategy Officer verkauft Aktien von Insmed im Wert von 5820061 USD (Insiderkauf)
	Schaeffer, Orlov S Nicole - Vorstand - Tag der Transaktion: 2025-11-12...

14.11.25 - 22:33	If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today (Benzinga)
	read more...

14.11.25 - 01:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Insmed im Wert von 5922795 USD (Insiderkauf)
	Flammer, Martina M.d. - Vorstand - Tag der Transaktion: 2025-11-11...

13.11.25 - 13:03	Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good (PR Newswire)
	More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER, N.J., Nov. 13, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to......

06.11.25 - 01:42	MSCI Adds 69 Companies, Removes 64 From Global Index in Review (Bloomberg)
	MSCI Inc. added 69 companies to its all country world index in its quarterly review, including CoreWeave Inc., Nebius Group and Insmed Inc....

06.11.25 - 00:01	Insiderhandel: Chief Legal Officer verkauft Aktien von Insmed im Wert von 4985910 USD (Insiderkauf)
	Smith, Michael Alexander - Vorstand - Tag der Transaktion: 2025-11-03...

05.11.25 - 13:06	Insmed To Present at November and December 2025 Investor Conferences (PR Newswire)
	BRIDGEWATER, N.J., Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will......

30.10.25 - 16:24	Insmed outlines $420M-$430M ARIKAYCE revenue target as BRINSUPRI launch gains traction (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 15:00	Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
	Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...

30.10.25 - 12:15	Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
	—BRINSUPRI ™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— —BRINSUPRI Total Revenue of $28.1 Million for the Third Quarter of 2025— —ARIKAYCE®......

30.10.25 - 12:12	Insmed GAAP EPS of -$1.75 misses by $0.42, revenue of $142M beats by $26.51M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.25 - 20:30	A Preview Of Insmed′s Earnings (Benzinga)
	read more...

29.10.25 - 16:06	Insmed Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.10.25 - 22:09	Insmed Ranks No. 1 on Science′s 2025 Top Biopharma Employers List (PR Newswire)
	—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J., Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients......

17.10.25 - 15:00	Sanofi and Insmed among winners of EU drug recommendations this week (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

16.10.25 - 13:03	Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025 (PR Newswire)
	—Data on Structural Lung Changes from a High-Resolution CT Substudy to be Presented as Late-Breaker— —Additional Analyses Will Highlight Efficacy, Symptom Reduction, and Biomarker Suppression in Patients with Non-Cystic Fibrosis Bronchiectasis— BRIDGEWATER, N.J., Oct. 16, 2025......

15.10.25 - 13:06	Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025 (PR Newswire)
	BRIDGEWATER, N.J., Oct. 15, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its......

08.10.25 - 16:36	This ′Strong Buy′ Stock Is Trading at New 20-Year Highs (Barchart)
	Insmed (INSM) is a biopharmaceutical company with strong momentum. Shares are trading at new 20-year highs. INSM has surged 128% over the past year. Analysts expect robust revenue and earnings growth,......

25.09.25 - 21:51	Spotlight on Insmed: Analyzing the Surge in Options Activity (Benzinga)
	Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ: INSM) revealed 29 unusual trades. read more...

22.09.25 - 13:03	Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 (PR Newswire)
	—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session— —New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of Brensocatib in Japanese Patients with Non-Cystic......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer ernten will, muß erst den Samen streuen. - William Shakespeare

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram